Bayer AG

Bayer AG

Health CarePharmaceuticals & Biotechnology
  • Price (EUR)97.92
  • Today's Change-0.52 / -0.53%
  • Shares traded2.02m
  • 1 Year change-6.83%
  • Beta0.9936
Data delayed at least 15 minutes, as of Feb 23 2018 16:35 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Bayer AG had relatively flat revenues (46.09bn to 46.77bn), though the company grew net income 10.24% from 4.11bn to 4.53bn. A reduction in the cost of goods sold as a percentage of sales from 45.65% to 43.39% was a component in the net income growth despite flat revenues.
Gross margin64.09%
Net profit margin9.76%
Operating margin15.87%
Return on assets4.87%
Return on equity12.16%
Return on investment6.21%
More ▼

Cash flow in EURView more

In 2016, Bayer AG did not generate a significant amount of cash. However, the company earned 9.09bn from its operations for a Cash Flow Margin of 19.44%. In addition the company used 8.73bn on investing activities and also paid 350.00m in financing cash flows.
Cash flow per share7.46
Price/Cash flow per share12.53
Book value per share44.98
Tangible book value per share12.50
More ▼

Balance sheet in EURView more

Bayer AG has a Debt to Total Capital ratio of 30.20%, a lower figure than the previous year's 70.60%.
Current ratio2.06
Quick ratio1.61
Total debt/total equity0.4333
Total debt/total capital0.302
More ▼

Growth rates in EUR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.00% and 5.21%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)1.88%
Div growth rate (5 year)10.35%
Payout ratio (TTM)60.63%
EPS growth(5 years)11.38
EPS (TTM) vs
TTM 1 year ago
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.